{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:44:36Z","timestamp":1793051076723,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-14045"],"award-info":[{"award-number":["DISC2-14045"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-14097"],"award-info":[{"award-number":["DISC2-14097"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BAKAR Spark award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipid nanoparticles (LNPs) have great potential as nucleic acid delivery vehicles; however, they trigger the production of inflammatory cytokines, which limits their medical applications. Developing non-inflammatory LNPs is challenging because the LNP\u2019s ionizable lipid and the process of endosomal disruption are the major sources of LNP toxicity but are also essential for delivering nucleic acids. Here we demonstrate that ionizable lipids containing a carboxylic acid and an amine (termed S-lipid) switch their charged state between the pHs of 7.4 and 4.0, allowing them to generate LNPs (termed switchable nanoparticles) that efficiently encapsulate nucleic acid and trigger endosomal release without activation of the TLR4, complement, galectin-8 and platelet activating factor signalling pathways. Finally, we demonstrate that switchable nanoparticles are better at treating lipopolysaccharide-induced acute lung injury than traditional LNPs because they do not exacerbate pre-existing inflammation. Collectively, these results demonstrate that negatively charged ionizable lipids can mitigate the toxicity of LNPs.<\/jats:p>","DOI":"10.1038\/s41565-026-02262-6","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:02:34Z","timestamp":1788858154000},"page":"1479-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-1836","authenticated-orcid":false,"given":"Dengpan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5545-5238","authenticated-orcid":false,"given":"Hesong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Ahmadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-890X","authenticated-orcid":false,"given":"Kewa","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2777-717X","authenticated-orcid":false,"given":"Kaycee","family":"Sapasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3163-8803","authenticated-orcid":false,"given":"Atip","family":"Lawanprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sopida","family":"Pimcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan T.","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3754-7826","authenticated-orcid":false,"given":"Zoe O.","family":"Enders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8256-3867","authenticated-orcid":false,"given":"Benjamin W.","family":"Burgstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-2902","authenticated-orcid":false,"given":"Antonino","family":"Calio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Dankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei S.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-3627","authenticated-orcid":false,"given":"Aijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-7337","authenticated-orcid":false,"given":"Niren","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2262_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","volume":"8","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary, N. et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat. Biomed. Eng. 8, 1483\u20131498 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2262_CR2","doi-asserted-by":"publisher","first-page":"e10556","DOI":"10.1002\/btm2.10556","volume":"8","author":"M Kim","year":"2023","unstructured":"Kim, M. et al. Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety. Bioeng. Transl. Med. 8, e10556 (2023).","journal-title":"Bioeng. Transl. Med."},{"key":"2262_CR3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/vaccines12101148","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. Vaccines 12, 1148 (2024).","journal-title":"Vaccines"},{"key":"2262_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E. et al. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2262_CR5","doi-asserted-by":"publisher","first-page":"603039","DOI":"10.3389\/fimmu.2020.603039","volume":"11","author":"NM La-Beck","year":"2020","unstructured":"La-Beck, N. M., Islam, M. R. & Markiewski, M. M. Nanoparticle-induced complement activation: implications for cancer nanomedicine. Front. Immunol. 11, 603039 (2020).","journal-title":"Front. Immunol."},{"key":"2262_CR6","doi-asserted-by":"publisher","first-page":"113709","DOI":"10.1016\/j.jconrel.2025.113709","volume":"382","author":"A Cavegn","year":"2025","unstructured":"Cavegn, A. et al. Intracellular processing of DNA-lipid nanoparticles: a quantitative assessment by image segmentation. J. Control. Release 382, 113709 (2025).","journal-title":"J. Control. Release"},{"key":"2262_CR7","doi-asserted-by":"publisher","first-page":"113641","DOI":"10.1016\/j.jconrel.2025.113641","volume":"381","author":"SG Moosavi","year":"2025","unstructured":"Moosavi, S. G., Rahiman, N., Jaafari, M. R. & Arabi, L. Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases. J. Control. Release 381, 113641 (2025).","journal-title":"J. Control. Release"},{"key":"2262_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","volume":"344","author":"H Parhiz","year":"2022","unstructured":"Parhiz, H. et al. Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE). J. Control. Release 344, 50\u201361 (2022).","journal-title":"J. Control. Release"},{"key":"2262_CR9","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","volume":"33","author":"HM Nguyen","year":"2025","unstructured":"Nguyen, H. M. et al. mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions. Mol. Ther. 33, 2872\u20132885 (2025).","journal-title":"Mol. Ther."},{"key":"2262_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51056-8","volume":"15","author":"X Bai","year":"2024","unstructured":"Bai, X. et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. Nat. Commun. 15, 6844 (2024).","journal-title":"Nat. Commun."},{"key":"2262_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35637-z","volume":"14","author":"X Han","year":"2023","unstructured":"Han, X. et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat. Commun. 14, 75 (2023).","journal-title":"Nat. Commun."},{"key":"2262_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20903-3","volume":"12","author":"F Rizvi","year":"2021","unstructured":"Rizvi, F. et al. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat. Commun. 12, 613 (2021).","journal-title":"Nat. Commun."},{"key":"2262_CR13","doi-asserted-by":"publisher","first-page":"eado4791","DOI":"10.1126\/sciadv.ado4791","volume":"10","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice. Sci. Adv. 10, eado4791 (2024).","journal-title":"Sci. Adv."},{"key":"2262_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00204-024-03912-1","volume":"99","author":"JH Ahn","year":"2025","unstructured":"Ahn, J. H. et al. Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model. Arch. Toxicol. 99, 755\u2013773 (2025).","journal-title":"Arch. Toxicol."},{"key":"2262_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/ph16081088","volume":"16","author":"T Korzun","year":"2023","unstructured":"Korzun, T. et al. From bench to bedside: implications of lipid nanoparticle carrier reactogenicity for advancing nucleic acid therapeutics. Pharmaceuticals 16, 1088 (2023).","journal-title":"Pharmaceuticals"},{"key":"2262_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1248\/bpbreports.2.4_48","volume":"2","author":"AY AlBaloul","year":"2019","unstructured":"AlBaloul, A. Y., Sato, Y., Maishi, N., Hida, K. & Harashima, H. Two modes of toxicity of lipid nanoparticles containing a pH-sensitive cationic lipid on human A375 and A375-SM melanoma cell lines. BPB Rep. 2, 48\u201355 (2019).","journal-title":"BPB Rep."},{"key":"2262_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2262_CR18","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085\u20132096 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2262_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/biomedicines9050530","volume":"9","author":"I Vlatkovic","year":"2021","unstructured":"Vlatkovic, I. Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety. Biomedicines 9, 530 (2021).","journal-title":"Biomedicines"},{"key":"2262_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo, E. et al. Low immunogenicity of LNP allows repeated administrations of CRISPR\u2013Cas9 mRNA into skeletal muscle in mice. Nat. Commun. 12, 7101 (2021).","journal-title":"Nat. Commun."},{"key":"2262_CR21","doi-asserted-by":"publisher","first-page":"120528","DOI":"10.1016\/j.biomaterials.2020.120528","volume":"268","author":"MA Jackson","year":"2021","unstructured":"Jackson, M. A. et al. Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers. Biomaterials 268, 120528 (2021).","journal-title":"Biomaterials"},{"key":"2262_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","volume":"154-155","author":"E Samaridou","year":"2020","unstructured":"Samaridou, E., Heyes, J. & Lutwyche, P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv. Drug Deliv. Rev. 154-155, 37\u201363 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2262_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","volume":"30","author":"SM Moghimi","year":"2022","unstructured":"Moghimi, S. M. & Simberg, D. Pro-inflammatory concerns with lipid nanoparticles. Mol. Ther. 30, 2109\u20132110 (2022).","journal-title":"Mol. Ther."},{"key":"2262_CR24","doi-asserted-by":"crossref","unstructured":"Ongun, M., Lokras, A. G., Foged, C. & Thakur, A. In Messenger RNA Therapeutics (eds S. Jurga & J. Barciszewski) 237\u2013255 (Springer, 2022).","DOI":"10.1007\/978-3-031-08415-7_11"},{"key":"2262_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52685-1","volume":"14","author":"GB Schober","year":"2024","unstructured":"Schober, G. B., Story, S. & Arya, D. P. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. Sci. Rep. 14, 2403 (2024).","journal-title":"Sci. Rep."},{"key":"2262_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jconrel.2023.07.058","volume":"361","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. et al. The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles. J. Control. Release 361, 361\u2013372 (2023).","journal-title":"J. Control. Release"},{"key":"2262_CR27","doi-asserted-by":"publisher","first-page":"e10213","DOI":"10.1002\/btm2.10213","volume":"6","author":"M Schlich","year":"2021","unstructured":"Schlich, M. et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng. Transl. Med. 6, e10213 (2021).","journal-title":"Bioeng. Transl. Med."},{"key":"2262_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01124-x","volume":"10","author":"AE Zelkoski","year":"2025","unstructured":"Zelkoski, A. E. et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4. npj Vaccines 10, 73 (2025).","journal-title":"npj Vaccines"},{"key":"2262_CR29","doi-asserted-by":"publisher","first-page":"e0125215","DOI":"10.1371\/journal.pone.0125215","volume":"10","author":"N Grote Beverborg","year":"2015","unstructured":"Grote Beverborg, N. et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS ONE 10, e0125215 (2015).","journal-title":"PLoS ONE"},{"key":"2262_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1161\/CIRCULATIONAHA.108.844662","volume":"121","author":"AMS Belonje","year":"2010","unstructured":"Belonje, A. M. S. et al. Endogenous erythropoietin and outcome in heart failure. Circulation 121, 245\u2013251 (2010).","journal-title":"Circulation"},{"key":"2262_CR31","first-page":"829","volume":"54","author":"H Xiao","year":"2025","unstructured":"Xiao, H. et al. A naturally derived lipopeptide lipid nanoparticle platform enabling multiple nucleic acids delivery. Bioact. Mater. 54, 829\u2013849 (2025).","journal-title":"Bioact. Mater."},{"key":"2262_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41587-025-02556-5","volume":"44","author":"MN Patel","year":"2026","unstructured":"Patel, M. N. et al. Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids. Nat. Biotechnol. 44, 79\u201389 (2026).","journal-title":"Nat. Biotechnol."},{"key":"2262_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"2262_CR34","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1038\/s41596-020-0393-6","volume":"15","author":"MA Dobrovolskaia","year":"2020","unstructured":"Dobrovolskaia, M. A. & Afonin, K. A. Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles. Nat. Protoc. 15, 3678\u20133698 (2020).","journal-title":"Nat. Protoc."},{"key":"2262_CR35","doi-asserted-by":"publisher","first-page":"e202110137","DOI":"10.1083\/jcb.202110137","volume":"221","author":"P Paramasivam","year":"2022","unstructured":"Paramasivam, P. et al. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. J. Cell Biol. 221, e202110137 (2022).","journal-title":"J. Cell Biol."},{"key":"2262_CR36","doi-asserted-by":"publisher","first-page":"e0254985","DOI":"10.1371\/journal.pone.0254985","volume":"16","author":"S Taghavi","year":"2021","unstructured":"Taghavi, S. et al. Interleukin-22 mitigates acute respiratory distress syndrome (ARDS). PLoS ONE 16, e0254985 (2021).","journal-title":"PLoS ONE"},{"key":"2262_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12865-022-00511-6","volume":"23","author":"C Yu","year":"2022","unstructured":"Yu, C. et al. Interleukin-22 protects from endotoxemia by inducing suppressive F4\/80Ly6GLy6C cells population. BMC Immunol. 23, 45 (2022).","journal-title":"BMC Immunol."},{"key":"2262_CR38","doi-asserted-by":"publisher","first-page":"17128","DOI":"10.1021\/acs.analchem.4c02399","volume":"96","author":"J Couture-Senecal","year":"2024","unstructured":"Couture-Senecal, J., Natraj, J. & Khan, O. F. A cell-free kinetic analysis of ionizable lipid hydrolysis. Anal. Chem. 96, 17128\u201317134 (2024).","journal-title":"Anal. Chem."},{"key":"2262_CR39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1124\/dmd.122.001194","volume":"51","author":"D Burdette","year":"2023","unstructured":"Burdette, D. et al. Systemic exposure, metabolism, and elimination of [(14)C]-labeled amino lipid, lipid 5, after a single administration of mRNA encapsulating lipid nanoparticles to Sprague\u2013Dawley rats. Drug Metab. Dispos. 51, 804\u2013812 (2023).","journal-title":"Drug Metab. Dispos."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02262-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:48:37Z","timestamp":1791949717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02262-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1038\/s41565-026-02262-6","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: H.H., K.G. and N.M. own equity in Opus Biosciences. N.M. is also a founder of and equity holder in BreezeBio. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}